Large-scale trials with angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT 1 )-receptor blockers have clearly shown that blockade of the reninangiotensin system reduces the deterioration in renal function associated with diabetes. AT 1 -receptor blockers represent a more rational approach to blockade of this system than ACE inhibitors, due to the presence of non-ACE pathways of angiotensin II formation. Studies in healthy volunteers maintained on a low-salt diet indicate that such pathways account for approximately 30-40% of total angiotensin II formation, and this figure increases to 60-70% in individuals maintained on a high-salt diet (resembling the situation in most human populations). Activation of the renin-angiotensin system
Introduction
The demonstration that treatment with angiotensin converting enzyme (ACE) inhibitors significantly reduces the progression of diabetic nephropathy 1 focused attention on the role of the reninangiotensin system in the kidney, and led to the widespread use of ACE inhibitor therapy in patients at risk of nephropathy. Moreover, recent large outcome studies with angiotensin II type 1 (AT 1 )-receptor blockers have shown that these agents reduce the deterioration in renal function, and delay the onset of end-stage renal failure, in diabetic patients. [2] [3] [4] In the Irbesartan Diabetic Nephropathy Trial (IDNT) 2 and the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) 3 study, treatment with an AT 1 -receptor blocker reduced the incidence of end points by approximately 20%. By contrast, in the Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA II) study, 4 the onset of overt nephropathy was reduced by 39% in patients receiving irbesartan, 150 mg, and by 70% in those receiving 300 mg. Such findings highlight the importance of early inter- vention in diabetic patients with microalbuminuria, and of using adequate doses to achieve effective receptor blockade, and raise the question of how blockade of the renin-angiotensin system can achieve such substantial risk reductions in an essentially metabolic disease.
Therapeutic targets for blockade of the renin-angiotensin system
Blockade of the renin-angiotensin system was first achieved with ACE inhibitors, which were developed in the 1970s after the chance finding that a component of pit viper venom had a powerful hypotensive effect. Arguably, however, a pharmacologist aiming to block the renin-angiotensin target would not have selected ACE as a therapeutic target. Renin is the rate-limiting step in the pathway leading to angiotensin II formation (Figure 1) , and thus would represent a rational target for intervention; however, the development of suitable candidate compounds has proved difficult because of problems with synthesis and bioavailability. 5 Moreover, angiotensin II is produced by a number of pathways that do not involve ACE, such as chymase, trypsin and cathepsin G (Figure 1) . Blockade of the AT 1 -receptor thus represents a more rational therapeutic target than ACE inhibition. 
Non-ACE pathways of angiotensin II formation
Evidence for the contribution of non-ACE pathways to angiotensin II formation in the human cardiovascular system comes from a study in which angiotensin II was measured in plasma and myocardial tissue from normal and failing hearts obtained at transplantation. 6 In plasma, conversion of angiotensin I to angiotensin II can be completely blocked by ACE inhibitors; by contrast, in myocardial membrane preparations, ACE inhibitors have only a limited effect on angiotensin II formation whereas serine protease inhibitors reduce angiotensin formation by approximately 80%. Similar results were obtained in studies with human gastroepiploic artery preparations, in which chymase inhibitors reduced the contractile response to angiotensin II, formed locally following addition of angiotensin I, to a greater extent than ACE inhibitors, and the two inhibitors in combination produced almost complete abolition of the response. 7 In these experiments, approximately 30-40% of angiotensin II formation was attributable to ACE, and the remainder to non-ACE pathways. There are, however, marked species differences; in humans and other primates, angiotensin I is the sole substrate for chymase and angiotensin II is the sole product, whereas in rodents and rabbits this enzyme is primarily responsible for degradation of angiotensin II, rather than formation. For this reason, studies with animal models have often been misleading. An example of this is provided by early studies in rats, which showed that ACE inhibitors were strong inhibitors of neointima formation after vascular injury. 8, 9 However, large clinical trials, notably the MERCATOR Study, 10 failed to show significant beneficial effects of ACE inhibitors on restenosis rates after percutaneous transluminal coronary angioplasty. It is now widely accepted that this discrepancy between animal studies and clinical trial outcome is largely due to the presence of non-ACE pathways of angiotensin II formation in humans.
Non-ACE pathways in the kidney
The relative contributions of ACE and non-ACE pathways of angiotensin II formation in the human kidney have been investigated in experiments in healthy volunteers fed a low-salt diet. 11 If the increase in renal plasma flow that occurs during blockade of the renin-angiotensin system were solely attributable to blockade of angiotensin II produced via ACE, then renin inhibitors, ACE inhibitors, and AT 1 -receptor blockers should produce similar results. By contrast, if the renal vascular response is partly due to a reduced breakdown of vasodilator kinins such as bradykinin following ACE inhibition, the effect of ACE inhibitors would be expected to be greater than that of renin inhibitors or AT 1 -receptor blockers.
In one study, participants received 90-min infusions of the renin inhibitor enalkiren, 256 g/kg or 512 g/kg, at 2-day intervals. 12 The lower dose was at the top of the dose-response curve for inhibition of angiotensin II formation. The increase in renal plasma flow following administration of enalkiren was substantially greater than that seen in previous studies with ACE inhibitors, and was dosedependent; a greater response was achieved with the higher dose, even though plasma angiotensin II concentrations were not further reduced (Figure 2 ). This suggests that the response to the renin inhibitor was attributable to inhibition of non-ACE pathways within the kidney. This study was repeated using different renin inhibitors and three ACE inhibitors, each at the top of their dose-response ranges. 13 The combined data from these studies showed that the renal vascular response to renin inhibition was markedly greater than the response to ACE inhibition (approximately 140 mL/min/1.73 m 2 vs 90-100 mL/min/1.73 m 2 ). In further studies, the AT 1 -receptor blockers candesartan, irbesartan and eprosartan were found to produce comparable increases in renal plasma flow to renin inhibitors. 11, 14, 15 Together, these data suggest that the renal vascular response to ACE inhibition systematically under-estimates the contribution of angiotensin II to renovascular tone during activation of the renin-angiotensin system.
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Subsequent studies used the relative renal vascular response to ACE inhibitors and AT 1 -receptor blockers as an index of non-ACE formation of angiotensin II. In one series of experiments, 65 healthy volunteers maintained on low-salt or high-salt diets received either captopril, 25 mg, or candesartan cilexetil, 16 mg, and renal haemodynamic responses were measured over 4 h. 16 In volunteers maintained on a low-salt diet, the increase in renal plasma flow following candesartan (mean 165 ± 14 mL/min/1.73 m 2 ) was significantly greater than that following captopril (118 ± 12 mL/min/1.73 m 2 , P Ͻ 0.01), as expected. In volunteers maintained on a high-salt Journal of Human Hypertension diet, the responses to both agents were attenuated ( Figure 3) . In this situation, however, the response to candesartan was even more markedly greater than the response to captopril (97 ± 20 mL/min/1.73 m 2 vs 30 ± 15 mL/min/1.73 m 2 , respectively, P Ͻ 0.01; Figure 3 ), since the response to captopril was diminished to a greater extent than the response to candesartan. This suggests that the high-salt diet had less effect on non-ACE pathways of angiotensin II formation than on ACE; in this situation, non-ACE pathways accounted for approximately 60-70% of renal angiotensin II formation, compared with 30-40% in volunteers maintained on low-salt diets. This finding may be clinically relevant since the daily salt intake of most people is closer to that in the highsalt diet used in this study than to the low salt-diet. Since non-ACE pathways appear to make a greater contribution to angiotensin II production when salt intake is high, AT 1 -receptor blockers might be expected to produce a greater therapeutic effect than ACE inhibitors.
Activation of the renin-angiotensin system in diabetic nephropathy
In contrast to diabetic retinopathy, the incidence of which increases progressively with time, the incidence of diabetic nephropathy reaches a plateau after 20-25 years, by which time approximately 30-40% of patients with type 1 diabetes have clinical nephropathy. The risk of developing frank nephropathy is determined by both glycaemic control 17 and genetic factors. For example, there is a strong association between ACE insertion/deletion (I/D) polymorphism and the risk of nephropathy. 18, 19 In subjects maintained on a high-salt diet, the renal vascular response to captopril is markedly increased in patients with type 1 diabetes, compared with non-diabetic individuals. 15 Glomerular hyperfiltration, increased glycosylated haemoglobin, and high plasma renin activity, were all factors predisposing to an increased response to captopril (unpublished observations).
In a study involving 12 patients with type 1 diabetes who were maintained on a high-salt diet, patients received captopril, 25 mg, and candesartan cilexetil, 16 mg, on separate occasions during the same week. 20 Renal plasma flow and glomerular filtration were measured before, and for 4 h after, administration. Both drugs produced a significant increase in renal plasma flow, compared with baseline, with no change in glomerular filtration rate. There was a strong correlation between the responses to the two agents (r = 0.86, P Ͻ 0.001; Figure 4 ), indicating that the effect of captopril is mediated primarily via suppression of angiotensin II production.
In contrast to type 1 diabetes, type 2 diabetes is normally characterised by low levels of plasma renin activity. Despite this, the renal vascular response to captopril is markedly greater in patients with type 2 diabetes than in those with type 1 diabetes, indicating greater activation of the reninangiotensin system (unpublished observations).
Comparison of the renal vascular responses to captopril and candesartan in patients with type 2 diabetes showed an even stronger correlation than in type 1 diabetes (r = 0.886, P = 0.001). Such findings indicate that angiotensin II is a major risk factor for tissue damage in type 2 diabetes.
Dose issues for suppression of the renin-angiotensin system
Studies such as those described above show that the renin-angiotensin system is activated in diabetes, and it is widely accepted that inhibition of this system reduces the progression of nephropathy in diabetic patients. These renoprotective effects appear to be independent of, and additional to, effects on blood pressure. However, most outcome trials with inhibitors of the renin-angiotensin system have used the doses needed to reduce blood pressure, and there is increasing evidence that optimal renoprotective effects may require higher doses.
In studies using the remnant kidney model in rats, high-dose treatment with ACE inhibitors produced significantly greater reductions in glomerulosclerosis following subtotal nephrectomy than lowdose treatment. 21 Similarly, dose-response studies in humans have shown that ACE inhibitors exert renoprotective effects at doses higher than those needed to control blood pressure. In one such study with lisinopril, for example, the maximal reduction in blood pressure was seen with the lowest dose (5 mg); however, increasing reductions in proteinuria were seen with doses of between 5 mg and 20 mg. 22 Similar findings have been reported with AT 1 -receptor blockers. In one study, for example, hypertensive patients with non-diabetic renal disease received placebo, losartan, 50 mg and 100 mg, and placebo for 1 month each in sequence. 23 Both blood pressure and urinary protein excretion were reduced following treatment with losartan, 50 mg; the higher dose produced a further reduction in proteinuria but had no additional effect on blood pressure.
In a recent study, 10 patients with proteinuria (Ͼ1.5 g/day; mean 4.4 g/day) were treated with candesartan cilexetil at initial doses of 16-32 mg/day, and after 1-2 months the doses were titrated upwards in 32 mg increments to a maximum of 96 mg/day. 24 Candesartan, 16-32 mg, produced a marked reduction in proteinuria, and further decreases were seen when doses were increased above the normal recommended range ( Figure 5 ); in patients receiving 96 mg/day, mean urinary protein excretion was reduced to 1.1 g/day. High-dose treatment appeared to be safe and well tolerated, although further investigation is necessary before specific recommendations can be made for clinical practice.
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Conclusions
Diabetic patients are at high risk of renal (and other) disease related to activation of the renin-angiotensin system because of the presence of multiple risk factors. These include genetic predisposition, hyperglycaemia leading to activation of the reninangiotensin system, 25 obesity and tissue injury. Early blockade of the renin-angiotensin system is therefore an important element of diabetes management.
